Piramal Pharma lifts FY27 outlook as quarterly revenue rises 28%
Indian drugmaker Piramal Pharma reported higher revenue and EBITDA for the quarter and half year, returned to a profit and raised its full-year revenue guidance.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Indian drugmaker Piramal Pharma has published its results for the second quarter and first half of fiscal 2027, which ended on September 30, 2026. The information comes from TradingView, which cites the company's press release.
Second-quarter revenue reached 2,617 crore rupees, up 28% year on year. For the half year, revenue rose 23% to 4,887 crore. Quarterly EBITDA jumped 72% to 385 crore, and its margin widened to 14.7% from 11.0% a year earlier. Net profit came in at 5 crore rupees, compared with a loss of 99 crore a year before.
The company credits higher capacity utilization, operating leverage and ongoing cost-reduction measures. It now expects revenue growth of 19% to 20% for the full fiscal year, an upgrade from its earlier outlook.
why it matters
This is one company's report, but it points to fast growth and widening margins in contract manufacturing for pharmaceuticals. Investors in India's pharma sector typically watch plant utilization and new order intake more than one-off items.
market impact
Piramal Pharma shares: stronger results and a raised outlook support the stock
- Piramal Pharma shares pressure up — profit turned positive, EBITDA margin widened and the outlook was raised
tags
instruments
sources
- Piramal Pharma Limited Announces Results for Q2 and H1 FY27 — TradingView, 27 October 2026 at 19:23 UTC
- Piramal Pharma Limited Announces Results for Q2 and H1 FY27 — TradingView, 27 October 2026 at 19:28 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗